ClinicalTrials.gg
RecruitingNCT04798950Updated Jun 15, 2026

Bronchi Dilation in Polynesian Patients: Monocentric Retrospective Study

An observational study in Polynesian Bronchiectasis, sponsored by Centre Hospitalier Intercommunal Creteil. Recruiting at 1 site in French Polynesia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Centre Hospitalier Intercommunal Creteil · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

The study hypothesis is that dilations of idiopathic bronchi are particularly common in French Polynesia, and that there are arguments in favour of an underlying genetic factor.

The study will retrieve retrospective data in the history of bronchial dilation, patients' personal and family history, microbiological and scannographic data, and the latest cardio respiratory checkup.

02

Conditions studied

  • Polynesian Bronchiectasis

Browse trials for

Keywords

  • bronchi dilatation
03

In context

Kartagener Syndrome

21 studies on the registry are indexed under Kartagener Syndrome; 4 are open to participants now.

This study's planned enrollment of 500 is above the median of 200 across 17 observational studies indexed under Kartagener Syndrome.

Browse Kartagener Syndrome studies →

Lead sponsor

Centre Hospitalier Intercommunal Creteil is the lead sponsor of 132 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

500 patients with bronchial dilatation over the study period: Jan 1, 2010 to Dec 31, 2020

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Polynesian patient
  • Patient with bronchial dilation followed by Centre hospitalier de Polynesie Francaise or patient with bonchial dilation no longer consulting in the hospital over the study period Jan 1, 2010 to Dec 31, 2020

Exclusion criteria

Exclusion Criteria:

  • Expressed refusal to participate in the study for patients undergoing follow-up
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Describe the detailed phenotype of bronchi dilation in the Polynesian population

    * Clinical criteria: age of onset, personal or family history, smoking Changes in respiratory function * Infectious complications: types of bronchial colonization (bacterial, mycobacterial and mycological) * Scantographic aspect: Appearance of bronchectasis: cylindrical, varicose orcious, cystic Distributions: LSD, LM, LID, LSG, LIG

    Time frame: Day 1

Secondary outcomes

  1. Highlighting indirect arguments for a genetic cause

    Age of onset of symptoms, frequency of so-called "idiopathic" bronchi dilatation, frequency of inbreeding, familial history

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
  • CH Polynésie Francaise
    Papeete, French Polynesia
    Recruiting
    • Eric PARRAT, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Jul 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 16, 2021
StartActual
Jun 1, 2025
Primary completionActual
Jul 1, 2025
CompletionEst.
Jun 1, 2027
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04798950
Responsible party
Sponsor
First posted
Mar 16, 2021
Start date
Jun 1, 2025
Primary completion
Jul 1, 2025
Completion
Jun 1, 2027 (estimated)
Last update
Jun 15, 2026

Study contacts

Benoit Douvry, MD
Contact
Benoit.Douvry@chicreteil.fr
01 45 17 57 28
Eric PARRAT, MD
Contact
eric.parrat@cht.pf
00 689 87707790

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion